Corbus Pharmaceuticals Holdings Stock
Corbus Pharmaceuticals Holdings, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Yuval Cohen
- Employees
- 36
- Market cap
- $87 M
- IPO
- 27/10/2014
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601,…
Corbus Pharmaceuticals Holdings stock: price history
1D
+4.4%
1W
-16.0%
1M
-37.7%
6M
-57.3%
YTD
-44.5%
1Y
-76.3%
2Y
-76.4%
5Y
-85.2%
10Y
-98.3%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~14% weaker price swings than usual
Ask the agents about Corbus Pharmaceuticals Holdings
Analyst assessment of Corbus Pharmaceuticals Holdings
PRICE TARGET LOW
US$33.00
CONSENSUS
US$33.67
MEDIAN
US$33.00
PRICE TARGET HIGH
US$35.00
0
STRONG BUY
14
BUY
2
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 14/09/2026
Corbus Pharmaceuticals Holdings stock metrics
P/E
-0.7
P/B
0.86
EV/EBITDA
-0.67
RETURN ON EQUITY
-34.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.5%
FLOAT SHARES
13,248,205
AVG. DAILY VOLUME (30D)
1,262,081
Insider transactions (SEC)
Ben Yong
Nicacio Leonardo Viana
Saxena Nishant C
Cohen Yuval
Moran Sean F.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Corbus Pharmaceuticals Holdings stock
What does Corbus Pharmaceuticals Holdings do?
Corbus Pharmaceuticals Holdings, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Yuval Cohen, the company employs around 36 people.
The IPO was on 27/10/2014; the stock trades on NASDAQ under the ticker CRBP.
What do analysts say about Corbus Pharmaceuticals Holdings stock?
16 analysts rate the stock, the consensus is Buy (as of 14/09/2026).
The average price target is US$33.67, ranging from US$33.00 to US$35.00, with a median of US$33.00.
This is an external assessment, not a statement by Market Jury.
When does Corbus Pharmaceuticals Holdings report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -14% stronger than usual.
Does Corbus Pharmaceuticals Holdings pay a dividend?
No, Corbus Pharmaceuticals Holdings currently does not pay a dividend.
Which stocks are comparable to Corbus Pharmaceuticals Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Corbus Pharmaceuticals Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Corbus Pharmaceuticals Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.